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INTRODUCTION: The present study compared the effect of combination therapy using human apolipoprotein(a) kringle
V (rhLK8) to conventional chemotherapy with paclitaxel for human ovarian carcinoma producing high or low levels of
vascular endothelial growth factor (VEGF).MATERIALS ANDMETHODS:Human ovarian carcinoma cells producing high
(SKOV3ip1) or low (HeyA8) levels of VEGF were implanted into the peritoneal cavity of female nude mice. Seven days
later, micewere randomized into four groups: control (vehicle), paclitaxel [5mg/kg, weekly intraperitoneal (i.p.) injection],
rhLK8 (50 mg/kg, daily i.p. injection), or the combination of paclitaxel and rhLK8. Mice were treated for 4 weeks and
examined by necropsy. RESULTS: In mice implanted with SKOV3ip1 cells, rhLK8 treatment had no significant effect on
tumor incidenceor the volumeof ascites but induced a significant decrease in tumorweight comparedwith controlmice.
Paclitaxel significantly reduced tumor weight and ascites volume, and combination treatment with paclitaxel and rhLK8
had an additive therapeutic effect. Similarly, in HeyA8 mice, the effect of combination treatment on tumor weight and
tumor incidence was statistically significantly greater than that of paclitaxel or rhLK8 alone. Immunohistochemical
analysis showed a significant decrease in microvessel density and a marked increase of apoptosis in tumor and tumor-
associated endothelial cells in response to combination treatmentwith paclitaxel and rhLK8.CONCLUSION:Collectively,in the study design; the collection, analysis, and interpretation of the data; the writing of the
manuscript; or in the decision to submit the manuscript for publication. In addition, the
authors have no potential conflicts of interest to disclose.
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chemotherapy could be effective for the treatment of ovarian carcinomas, regardless of VEGF status.
Translational Oncology (2014) 7, 368–376Introduction
Ovarian cancer is the leading cause of death from gynecological
malignancies [1]. Each year, more than 190,000 new cases of ovarian
cancer are diagnosed worldwide, which accounts for approximately 4%
of all cancers diagnosed in women [2]. Efforts to develop screening or
diagnostic tools for early detection of ovarian cancer have not been
successful; therefore, a significant number of patients are diagnosed in
advanced stages, requiring cytoreductive and systemic therapies such as
palliative surgery and chemotherapy, respectively. However, despite an
initial favorable response to chemotherapy [3,4], the heterogeneity and
genetic instability of ovarian cancer cells [5] often leads to the
development of drug resistance [6,7], resulting in increased cancer-
related mortality. The prognosis of patients with advanced ovarian
cancer has not improved over the last few decades [8], and the
development of novel therapeutic strategies is therefore of critical
importance [9]. Targeting relatively more homogenous and genetically
stable host organ microenvironments is a new strategy that was
introduced to overcome the drug resistance of tumor cells and produce
better therapeutic outcomes [10,11]. The establishment of a vascular
network supplying oxygen and nutrients to tumor cells is one of the
most important and critical steps of tumor progression [12].
Consequently, several clinical trials have tested the efficacy of
antiangiogenic molecules for blocking the interaction between tumor
cells and host factors for angiogenesis, but no significant improvement
has been achieved regarding the prognosis of ovarian cancer [2,13].
Kringle domains are found in many proteins with a diverse array of
functions including growth factors and proteases of the blood
coagulation and fibrinolysis pathways [14]. Several kringle domains in
these proteins have been identified as inhibitors of angiogenesis, even
though their parental proteins are not involved in angiogenesis. One of
these molecules, angiostatin, includes the first three (or four) kringle
domains of human plasminogen and has shown inhibitory effects on
angiogenesis in vitro and tumor growth in vivo in preclinical settings
[15]; however, in clinical trials, angiostatin did not show significant
anticancer effects or improve clinical outcomes [16]. Human
apolipoprotein(a) (apo(a)) also consists of tandemly repeated kringle
domains homologous to plasminogen kringle IV (KIV), a single copy
plasminogen kringle V homolog (KV), and an inactive protease
domain. Previously, we demonstrated that the KIV9, KIV10, and
KV domains of human apo(a), called LK68, inhibit angiogenesis
and tumor growth [17]. In addition, recombinant human apo(a)
KV (referred to as rhLK8) also showed antiangiogenic activity that
was almost equivalent to that of LK68 [18]. Recently, we showed
the therapeutic efficacy of targeting tumor-associated vasculature
with rhLK8 in experimental primary and metastatic (bone)
prostate carcinoma animal models [19], and on the basis of the
results of the preclinical study, rhLK8 has been successfully
translated into the phase I clinical trials. Studies determining the
indication of the treatment are being expanded.
In this study, we examined the biologic effect of human apo(a) KV
(rhLK8) on human ovarian cancer cells growing in the peritoneal cavity
of female nude mice. Furthermore, we examined the antiangiogenicmechanism of action of rhLK8 and showed that combination treatment
with human apo(a) KV and paclitaxel significantly inhibited tumor
growth by inducing apoptosis of tumor cells and tumor-associated
endothelial cells.
Materials and Methods
Human Ovarian Cancer Cell Lines and Human
Apolipoprotein(a) Kringle V (rhLK8)
Two human ovarian cancer cell lines were selected for this study:
SKOV3ip1, which expresses high levels of vascular endothelial growth
factor (VEGF) and is associated with increased ascites formation, and
HeyA8, which is characterized by low VEGF expression and no ascites
formation. Those cell lines are kind gifts of Dr Isaiah J. Fidler (The
University of TexasMDAnderson Cancer Center, Houston, TX) [20].
Cells were maintained in monolayer cultures in Eagle's minimal
essential medium supplemented with 10% FBS (Life Technologies,
Inc, Grand Island, NY), L-glutamine, pyruvate, non-essential amino
acids, two-fold vitamins, and penicillin-streptomycin (Invitrogen,
Carlsbad, CA) and incubated at 37°C in 5% CO2 and 95% air.
The rhLK8 protein was expressed and purified to homogeneity as
previously described [21]. Purified rhLK8 proteins were stored in
buffer containing 100 mM NaCl and 150 mM L-glycine (pH 4.2).
Paclitaxel (Taxol), purchased from Bristol-Myers Squibb (Princeton,
NJ), was diluted in saline for intraperitoneal (i.p.) injection.
Animals
Female athymic nude mice (NCI-nu) were purchased from the
Animal Production Area of the National Cancer Institute, Frederick
Cancer Research Facility (Frederick, MD). The mice were housed and
maintained under specific pathogen-free conditions in facilities
approved by the American Association for Accreditation of Laboratory
Animal Care and in accordance with all current regulations and
standards of theUSDepartment of Agriculture, theUSDepartment of
Health and Human Services, and the National Institutes of Health.
The mice were used in these experiments in accordance with
institutional guidelines when they were 8 to 12 weeks old.
Orthotopic Implantation of Ovarian Cancer Cells in
Animal Models
To establish peritoneal ovarian tumors, SKOV3ip1 or HeyA8 cells
were harvested from subconfluent cultures by a brief exposure to 0.25%
trypsin and 0.02% EDTA. The cells were washed once in serum-free
medium and resuspended in Ca2+-/Mg2+-free Hank's balanced salt
solution. Cell viability was determined by trypan blue exclusion. Only
single-cell suspensions of more than 95% viability were used for
injection. SKOV3ip1 (1 × 106) or HeyA8 (2.5 × 105) cells in 200 μl of
Ca2+-/Mg2+-free Hank's balanced salt solution were injected into the
peritoneal cavity of female nude mice as previously described [22].
Therapy Experiments
Seven days after cell implantation into the peritoneal cavity, the mice
were randomized into four treatment groups (n = 10mice per group) as
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and 150 mM L-glycine, pH 4.2) and weekly i.p. injection of saline; (2)
paclitaxel group, weekly i.p. injection of paclitaxel (5mg/kg) and daily i.
p. injection of vehicle; (3) rhLK8 group, daily i.p. injection of rhLK8
(50 mg/kg) and weekly i.p. injection of saline; and (4) combination
group, daily i.p. injection of rhLK8 (50mg/kg) andweekly i.p. injection
of paclitaxel (5 mg/kg). Treatments were continued for 4 weeks.
Necropsy and Preparation of Tissues
After 4 weeks of treatment, mice were killed by CO2 inhalation and
examined by necropsy. Body weight, tumor incidence, tumor weight,
and volume of ascites were recorded. Tumor tissues were embedded in
OCT compound (Miles, Inc, Elkhart, IN) and rapidly frozen in liquid
nitrogen or fixed in 10% buffered formalin for 24 hours and processed
for paraffin blocks.
Immunohistochemical Analyses of Proliferating Cell Nuclear
Antigen, Microvessel Density (CD31/platelet endothelial cell
adhesion molecule-1 (PECAM-1)), Bcl-2, Bax, and VEGF
Paraffin-embedded tissues were used for identification of proliferat-
ing cell nuclear antigen (PCNA)–positive cells as previously described
[23]. Frozen tissues used for identification of CD31/PECAM-1 were
sectioned (8-10 μm) and fixed in cold acetone. Immunohistochemistry
(IHC) procedures for PCNA and CD31/PECAM-1 were performed,
and all antibodies and reagents for IHC were purchased from sources
exactly as described previously [24]. Control samples exposed to
secondary antibody alone showed no specific staining.
For immunohistochemical staining of Bcl-2, Bax, and VEGF,
paraffin sections (4-6 μm thick) were mounted on positively charged
Superfrost slides (Fisher Scientific, Co, Houston, TX) and dried
overnight. Sections were deparaffinized in xylene, dehydrated with a
graded series of alcohol [100%, 95%, and 80% ethanol/double-distilled
H2O (vol/vol)], rehydrated in phosphate-buffered saline (PBS; pH7.5),
and then microwaved for 5 minutes to improve “antigen retrieval.”The
slides were rinsed twice with PBS, and endogenous peroxidase activity
was blocked with 3% hydrogen peroxidase in PBS for 12 minutes.
Nonspecific reactions were blocked by incubating the sections in a
solution containing 5%normal horse serum and 1%normal goat serum
for 20 minutes at room temperature (RT). Then, the slides were
incubated overnight at 4°Cwith a 1:50 dilution of polyclonal antibodies
against Bcl-2, Bax, or VEGF (Santa Cruz Biotechnology, Dallas, TX).
The samples were then rinsed three times with PBS and incubated in
HRP-conjugated goat anti-rabbit IgG at the appropriate dilutions for
60 minutes at RT. After rinsing with PBS, the slides were incubated for
5 minutes with DAB (Life Technologies, Inc), rinsed with distilled
water, counterstained with Gill's hematoxylin for 1 minute, and
mounted with Universal Mount (Life Technologies, Inc).
For quantification of PCNA expression, the number of positive cells
was quantified in 10 random fields at ×200 magnification. To quantify
mean vessel density, 10 random fields at ×100 magnification were
examined for each tumor, and the microvessels within those fields were
counted. A single microvessel was defined as a discrete cluster of cells
stained positive for CD31 and the presence of lumen [25].Immunof luorescence Double Staining for CD31
(Endothelial Cells) and terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) (Apoptotic Cells)
TUNEL assay was performed following CD31/PECAM-1 immuno-
fluorescent staining as described previously [26]. The TUNEL assay wasperformed using a commercially available apoptosis detection kit
(Promega, Madison, WI) with the following modifications. Samples
were fixed with 4%paraformaldehyde for 10minutes at RT,washed twice
with PBS for 5 minutes, and then incubated with 0.2% Triton X-100 for
15minutes at RT. After two 5-minute washes with PBS, the samples were
incubated with equilibration buffer (from kit) for 10 minutes at RT. The
equilibration buffer was drained, and the reaction buffer containing
equilibration buffer, nucleotide mix, and terminal deoxynucleotidyl
transferase (TdT) enzyme was added to the tissue sections and incubated
in a humid atmosphere at 37°C for 1 hour in the dark. The reaction was
terminated by immersing the samples in 2× SSC for 15minutes. Samples
were washed three times for 5 minutes to remove unincorporated
fluorescein-labeled deoxyuridine triphosphate (dUTP). The samples
were incubated with 300 μg/ml Hoechst 33342 for 10 minutes at RT.
Fluorescence bleaching was minimized by treating slides with a ProLong
anti-fade reagent (Life Technologies, Inc). The apoptotic index of tumor-
associated endothelial cells was determined by co-localization of CD31
and TUNEL staining. Endothelial cells and DNA fragmentation in
apoptotic cells were identified by red and green fluorescence, respectively,
and apoptotic endothelial cells were identified by yellow fluorescence
within the nucleus. Apoptotic tumor cells and tumor-associated
endothelial cells were identified and counted in five random fields at
×400. Images were captured by an Olympus BX-51 microscope
(Olympus America, Inc, Center Valley, PA).
Statistical Analyses
Tumor incidence, tumor weight, ascites volume (Mann-Whitney U
test), the number of PCNA-positive cells, and microvessel density
(MVD; CD31/PECAM-1) (unpaired Student's t test) were compared
in each treatment group. All values are expressed as means ± SD except
where indicated.Results
Effects of rhLK8 on the Tumor Growth
We determined the biologic effects of rhLK8 and paclitaxel on the
growth of SKOV3ip1 human ovarian cancer cells producing high levels
of VEGF injected into the peritoneal cavity of female nude mice.
Paclitaxel significantly reduced tumor weight [0.04 g (0-0.2 g) vs 0.98 g
(0.66-1.63g); median (range), P b .01)] and ascites [0.1 ml (0-0.2 ml)
vs 0.9 ml (0.5-1.6 ml); median (range), P b .05] compared to control
mice. No significant differences in tumor incidence or ascites volume
were detected between control mice andmice treatedwith rhLK8 alone;
however, rhLK8 significantly decreased tumor weight compared to the
control [Table 1; 0.65 g (0.01-1.3 g) vs 0.98 g (0.66-1.63 g); median
(range), P b .05]. Combination treatment with paclitaxel and rhLK8
had an additive effect on reducing tumor weight [control group 0.98 g
(0.66-1.63 g) vs combination group 0.01 g (0-0.14 g); median (range),
P b .01)] and the volume of ascites [control group 0.9ml (0.5-1.6ml) vs
0 ml (0-0.2 ml); median (range), P b .05].
The biologic effects of rhLK8 were also examined in mice injected
with HeyA8 human ovarian cancer cells producing low levels of VEGF
(Table 1). In these mice, tumor weight was significantly reduced by
treatment with paclitaxel or rhLK8 alone compared to that in control
mice [2.1 g (0-3.6 g) vs 4.0 g (0.2-7.2 g), P b .05 and 1.0 g (0-6.0 g) vs
4.0 g (0.2-7.2 g), P b .05, respectively]. Combination treatment with
paclitaxel and rhLK8 had a significant and synergistic effect on
decreasing tumor incidence (55.6 % vs 100%, P b .05) and tumor
weight [0.3 g (0-2.4 g) vs 4.0 g (0.2-7.2 g), P b .01]. No substantial
Table 2. Cellular Proliferation, Mean Vessel Density, and Apoptosis of Tumor-Associated Endothelial
Cells in Human Ovarian Cancers Growing in the Peritoneal Cavity of Female Nude Mice.
Treatment Groups PCNA
(Mean ± SD)
CD31
(Mean ± SD)
TUNEL+CD31+
(Mean ± SD)
SKOV3ip1 Control 108.4 ± 24.7 84.0 ± 27.5 0.6 ± 1.0
Paclitaxel 64.4 ± 17.3** 73.1 ± 20.4 4.0 ± 2.1*
rhLK8 74.0 ± 17.6 44.0 ± 9.7** 11.7 ± 4.0**
rhLK8 + paclitaxel 41.0 ± 12.8** 29.4 ± 5.7** 31.3 ± 9.4***
HeyA8 Control 98.4 ± 16.1 57.1 ± 18.5 0.2 ± 0.4
Paclitaxel 88.6 ± 16.9 40.0 ± 15.7* 2.7 ± 1.6*
rhLK8 76.1 ± 20.0 27.0 ± 6.1** 7.3 ± 3.4**
rhLK8 + paclitaxel 55.9 ± 14.2** 14.3 ± 5.0*** 26.4 ± 10.2***
Note: After 4 weeks of treatment, SKOV3ip1 or HeyA8 tumors were harvested and stained with PCNA,
CD31/PECAM, and/or TUNEL. For quantification of PCNA, mean vessel density, and apoptotic
endothelial cells, the number of positive cells was quantified in 10 random fields at ×200magnification and
×100 magnification and five random fields at ×400, respectively. *P b .05; **P b .01; ***P b .001.
Table 1. Therapy of Human Ovarian Cancers Growing in the Peritoneal Cavity of Female Nude
Mice.
Treatment Groups Tumor Incidence Tumor Weight (g)
[Median (range)]
Ascites (ml)
[Median (range)]
SKOV3ip1 Control 10/10 0.98 (0.66-1.63) 0.9 (0.5-1.6)
Paclitaxel 9/10 0.04 (0-0.20)** 0.1(0-0.2)*
rhLK8 10/10 0.65 (0.01-1.30)* 0.5 (0-1.9)
rhLK8 + paclitaxel 6/10 0.01 (0-0.14)** 0 (0-0.2)*
HeyA8 Control 10/10 4.0 (0.2-7.2) NA
Paclitaxel 8/10 2.1 (0-3.6)* NA
rhLK8 7/10 1.0 (0-6.0)* NA
rhLK8 + paclitaxel 5/9* 0.3 (0-2.4)** NA
Note: 1 × 106 SKOV3ip1 cells or 2.5 × 105 HeyA8 cells were implanted into the peritoneum of
female nude mice. Seven days later, treatment with vehicle, paclitaxel (5 mg/kg, weekly i.p.
injection), and rhLK8 (50 mg/kg, daily i.p. injection) alone or in combination with paclitaxel was
started and continued for 4 weeks. Tumor incidence, tumor weight, and ascites volume were
determined. *P b .05; **P b .01. NA, not applicable.
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groups (data not shown).
VEGF levels were ~10-fold higher in SKOV3ip1 cells than in
HeyA8 cells. Treatment of cells with rhLK8 for 48 hours had no
significant effect on VEGF levels in SKOV3ip1 or in HeyA8 cells
(Figure W1).
Determination of Cellular Proliferation and MVD
Cellular proliferative index was determined according to the number of
PCNA-positive cells, and MVD was determined by the number of
CD31-positive cells. The number of PCNA-positive cells was significantly
lower in paclitaxel-treated SKOV3ip1 tumors than in control mice (64.4
± 17.3 vs 108.4 ± 24.7, P b .01), whereas no significant reduction was
observed in response to rhLK8 treatment (74.0 ± 17.6 vs 108.4 ± 24.7,
P N .05). The most significant decrease in the number of PCNA-positive
cells was observed in SKOV3ip1 tumors treated with the combination of
paclitaxel and rhLK8 (41.0 ± 12.8 vs 108.4 ± 24.7, P b .01; Table 2 and
Figure 1A). In HeyA8 tumors, treatment with paclitaxel or rhLK8 alone
did not significantly decrease the number of PCNA-positive cells (88.6 ±
16.9 vs 98.4 ± 16.1, P N .05 and 76.1 ± 20.0 vs 98.4 ± 16.1, P N .05,
respectively); however, combination treatment significantly reduced the
number of PCNA-positive cells (55.9 ± 14.2 vs 98.4 ± 16.1, P b .01;
Table 2 and Figure 1B).
No significant differences in MVD were detected between control
and paclitaxel-treated SKOV3ip1 tumors (84.0 ± 27.5 vs 73.1 ± 20.4, P
N .05); however, treatment with rhLK8 alone and, in particular, the
combination of rhLK8 and paclitaxel significantly decreased MVD in
SKOV3ip1 tumors as compared with the controls (44.0 ± 9.7 vs 84.0 ±
27.5, P b .01 and 29.4 ± 5.7 vs 84.0 ± 27.5, P b 0.01, respectively;
Table 2 and Figure 2A). In HeyA8 tumors, MVD was significantly
reduced by treatment with paclitaxel compared with the control group
(40.0 ± 15.7 vs 57.1 ± 18.5, P b .05) and to a greater extent with rhLK8
alone (27.0 ± 6.1 vs 57.1 ± 18.5, P b .01) or the combination of
paclitaxel and rhLK8 (14.3 ± 5.0 vs 57.1 ± 18.5, P b .001; Table 2
and Figure 2B).
Determination of Apoptosis of Tumor Cells and Tumor-
Associated Endothelial Cells by Co-Localization of CD31
and TUNEL
Immunofluorescence double staining of CD31 (red) and TUNEL
(green) was performed to evaluate apoptosis of tumor cells and tumor-
associated endothelial cells in response to the different treatments.
Apoptosis of endothelial cells is indicated by co-localization, detected by
a yellow signal. In SKOV3ip1 tumors (Table 2 and Figure 3A), fewtumor cells or tumor-associated endothelial cells were apoptotic in the
control group. Paclitaxel treatment significantly induced apoptosis in
tumor-associated endothelial cells compared with the control group (4.0
± 2.1 vs 0.6 ± 1.0, P b .05). A more significant increase in apoptosis was
induced by rhLK8 alone (11.7 ± 4.0 vs 0.6 ± 1.0; P b .01), and the
combination of the two drugs enhanced this effect (31.3 ± 9.4 vs 0.6 ±
1.0, P b .001). A similar trend was observed in HeyA8 tumors (Table 2
and Figure 3B), in which paclitaxel significantly induced apoptosis
compared to the control group (2.7 ± 1.6 vs 0.2 ± 0.4, P b .05), and the
effect was enhanced by rhLK8 (7.3 ± 3.4 vs 0.2 ± 0.4, P b .01) or the
combination of the two drugs (26.4 ± 10.2 vs 0.2 ± 0.4,P b .001). In the
SKOV3ip1 and HeyA8 tumor models, apoptosis of tumor cells was
induced only in the paclitaxel treatment group and not in the rhLK8
treatment group, whereas the combination of paclitaxel and rhLK8
intensified the apoptosis of tumor cells (Figure 3). On the basis of the
findings byOltval and colleagues [27] suggesting that the Bax/Bcl-2 ratio
governs the sensitivity of cells to apoptotic stimuli, we analyzed the
expression of Bax and Bcl-2 proteins in the tumor tissues and observed
that there were no significant changes in Bcl-2 expression in the tumor
tissues from control and treatment groups, but the expression of BAX
was significantly increased in the tumor tissues from combination
treatment group of mice (Figure W2).
To investigate the effects of rhLK8 or paclitaxel treatment, as a single
agent or combination of two drugs, on the expression of VEGF in the
tumor tissues, immunohistochemical staining of VEGF was performed.
VEGF expression in SKOV3ip1 tumors was significantly higher than
that in HeyA8 tumors, compared to tumors of control groups (Figure
W3). Treatment of mice with either paclitaxel or rhLK8 did not
significantly alter the expression of VEGF; however, expression of
VEGF in tumors of HeyA8 was slightly increased in tumors of mice
treated with either paclitaxel or rhLK8 (Figure W3B). Treatment with
the combination of paclitaxel and rhLK8 significantly decreased the
expression of VEGF (Figure W3B).
Discussion
Ovarian tumors possess a rich vascular network that is highly dependent
on VEGF-mediated angiogenesis [28,29]. Therefore, many angiogen-
esis inhibitors have been evaluated in the preclinical and clinical settings
for the treatment of ovarian carcinoma [30]. One of themost extensively
studied vascular targeting molecules is bevacizumab (Avastin), which
neutralizes circulating VEGF and suppresses angiogenesis [31]. Recent
phase III clinical trials in first-line ovarian cancers showed that
bevacizumab prolonged progression-free survival when administered
in combination with chemotherapy [32]. However, the effect of anti-
Figure 1. Analysis of cellular proliferation. (A) In SKOV3ip1 tumors, paclitaxel significantly decreased the number of proliferative (PCNA-
positive) cells, and this effect was enhanced in response to combination treatment with paclitaxel and rhLK8. (B) In HeyA8 tumors,
treatment with paclitaxel alone or rhLK8 alone did not change the cellular proliferative index (PCNA-positive cells), but combination
treatment with paclitaxel and rhLK8 significantly decreased the number of PCNA-positive cells.
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with several clinical toxicities [33,34]. Moreover, tumor cells can escape
from prolonged anti-VEGF therapy by producing other proangiogenic
factors [35]. Therefore, the development of antiangiogenic drugs that are
effective independent of the VEGF status of tumors is critical.
Our results clearly showed the efficacy of antiangiogenic therapy
with rhLK8 in combination with paclitaxel on the proliferation of
human ovarian carcinoma cells producing high or low levels of VEGF
in a xenograft mouse model. We examined two human ovarian cancer
cell lines with significantly different VEGF levels and expected to find
differences in the biologic activity of the VEGF axis. Tumors derived
from SKOV3ip1 cells grew relatively slower, produced higher levels ofVEGF, induced the development of ascites, and showed higher
MVD, whereas HeyA8 cells formed larger tumors with lower VEGF
expression levels that did not produce ascites and showed lower
MVD. Treatment with paclitaxel or rhLK8 as a single agent
significantly reduced tumor size but not tumor incidence in both
models. Immunohistochemical analysis of tumor specimens revealed
that paclitaxel treatment inhibited tumor cell proliferation, whereas
rhLK8 showed minimal effects; however, rhLK8 treatment signifi-
cantly induced apoptosis of tumor-associated endothelial cells and
decreased MVD, whereas paclitaxel had no or a minimal effect.
Although rhLK8 significantly reduced tumor size in a limited period
of time (~4 weeks) by inducing apoptosis of tumor-associated
Figure 2.MVD of tumors by immunohistochemical staining of CD31. (A) In SKOV3ip1 tumors, rhLK8 significantly reduced the number of
CD31-positive cells, and this effect was enhanced by combination treatment with rhLK8 and paclitaxel. (B) In HeyA8 tumors, treatment
with paclitaxel alone significantly decreased MVD as determined by the number of CD31-positive cells, and this effect was intensified by
rhLK8 treatment and most significantly by the combination of paclitaxel and rhLK8.
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tumor cells nourished by the same vasculature, it did not affect tumor
cell proliferation. These findings suggest that the cytostatic nature of
angiogenesis inhibitors, including rhLK8, may limit their ability to
control the growth of cancer cells, and combination therapy with
chemotherapeutic agents may be necessary to enhance their
therapeutic efficacy and to prolong the median survival of patients
with ovarian cancer. In this study, we found that antiangiogenic and
antitumor efficacy was dramatically improved in mice treated with the
combination of paclitaxel and rhLK8. Our results are in agreement
with an increasing body of work demonstrating that the combinationof angiogenesis inhibitors with chemotherapeutic drugs significantly
improves treatment outcomes compared to single agent therapy.
Tumor blood vessels are irregular, dilated, tortuous, and leaky, which
leads to elevated tumor interstitial fluid pressure and thus inefficient
delivery of chemotherapeutic agents [36]. Antiangiogenic therapy
may induce the transient normalization of tumor vasculature, which
enhances the delivery of chemotherapeutic agents such as paclitaxel by
decreasing interstitial pressure, leading to an increase in therapeutic
efficacy [37]. In addition, rhLK8 may attenuate the survival pathway
of tumor-associated endothelial cells, which makes proliferating
tumor-associated endothelial cells more sensitive to anticycling drug,
Figure 3. Apoptosis of tumor cells and tumor-associated endothelial cells. Tumor specimens from (A) SKOV3ip1 or (B) HeyA8 tumors
were subjected to immunofluorescence double labeling, and the co-localization of signals for CD31 and TUNEL was determined.
Treatment with paclitaxel alone significantly induced apoptotic (TUNEL-positive, green) tumor cells and tumor-associated endothelial
cells (TUNEL-positive and CD31-positive, yellow), and this effect was intensified by treatment with rhLK8 alone. Combination treatment
(paclitaxel plus rhLK8) had the most significant effect on the induction of apoptosis.
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nation therapy with rhLK8 appear not to be limited to taxane-based
chemotherapy. Our preliminary data showed that combination
therapy of rhLK8 with gemcitabine or irinotecan (or 5-fluorouracil)
improved treatment outcomes than the corresponding treatment as a
single agent in the human pancreatic and colon carcinoma animal
models, respectively (Kim JS et al., unpublished data). In this context,
combination of rhLK8 with other chemotherapeutic agents such as
carboplatin or cisplatin, which have been regarded as the primary
treatment option of advanced ovarian cancer together with paclitaxel,was also expected to show improved treatment outcomes, although
appropriate preclinical and/or clinical evaluation of the combination
therapy will be critically required.
Paclitaxel significantly reduced the volume of ascites in SKOV3ip1
tumor–bearing mice but rhLK8 alone did not. However, the effect of
rhLK8 on decreasing MVD was more significant than that of
paclitaxel. These results are in agreement with prior findings
suggesting that ascites formation may depend on the levels of
VEGF (originally referred to as vascular permeability factor) produced
by tumor cells rather than MVD [38], because paclitaxel-treated
Translational Oncology Vol. 7, No. 3, 2014 Anti-angiogenic therapy with apo(a) kringle V Yu et al. 375tumors were smaller (and displayed a lower tumor burden) than those
treated with rhLK8 alone. Interestingly, rhLK8 as a single agent
significantly reduced tumor size, and this effect was more pronounced
in HeyA8 tumors producing low levels of VEGF. rhLK8 appears not
to target tumor cells but inhibits activated endothelial cells.
Therefore, antitumor efficacy of rhLK8 was independent on the
VEGF expression of the corresponding tumor cells. Because
SKOV3ip1 produced the profound amount of biologically active
VEGF, they have more biologic redundancy in the survival of tumor-
associated endothelial cells than HeyA8, which depends on more tight
and narrower angiogenesis activity. Therefore, when rhLK8 inhibits
angiogenesis of tumor-associated vasculature, there would be more
impact on the HeyA8 tumors. This may explain the synergistic
therapeutic effect of rhLK8 on HeyA8 cells. Collectively, these results
suggest that VEGF may not be a determinant of the response of
certain cancers to antiangiogenic therapy with rhLK8.
In this study, expression of VEGF was increased in HeyA8 tumors
of mice treated with paclitaxel or rhLK8. This may be from the local
hypoxic condition induced by impaired tumor vasculature caused by
either destruction of proliferating tumor-associated endothelial cells
by paclitaxel or suppressed angiogenesis by rhLK8. Because intrinsic
level of expression in SKOV3ip1 tumors was high, it was not altered
by the local hypoxia induced by the treatment with either paclitaxel or
rhLK8. Decreased expression of VEGF in tumors of mice treated by
the combination of paclitaxel and rhLK8 may reflect the decreased
biologic activity or, further, viability of tumor cells from additive or
synergistic effects on the induction of the apoptosis of tumor-
associated endothelial cells.
Previously, we showed that combination treatment with paclitaxel
and rhLK8 could be an effective therapy for prostate cancer metastatic
to the bone [19], as well as other solid tumors including colorectal
carcinoma, pancreatic carcinoma, renal cell carcinoma, and melano-
ma (data not shown); however, macroscopic (tumor incidence and
tumor size) or microscopic (cellular proliferation, MVD, or apoptosis)
responses to therapy with paclitaxel and rhLK8 were not observed in
orthotopic animal models of human lung cancer, PC14 cells, which
produce high levels of VEGF, and pleural effusion (Kim JS et al.,
unpublished data).
The mechanisms mediating the different responses to rhLK8
treatment between tumors growing in different organs are not clear.
One possible explanation is that rhLK8may have a differential effect on
the biologic properties of tumor-associated endothelial cells, because the
specific features of endothelial cells have been reported to be organ-
dependent [39,40]. Furthermore, the interaction of rhLK8 with
glucose-regulated protein 78 on the endothelial cell surface plays an
important role in rhLK8-mediated apoptosis of endothelial cells (Ahn
JH et al., unpublished data), although the impact of this interaction in
the endothelial cells of certain organs or that of interactions with other
target protein(s) or receptor(s) on the organ-specific therapeutic
outcomes mediated by rhLK8 remains unclear. Moreover, tumor cell
features such as the activation of some oncogenes and interactions with
components of the tumor microenvironment, such as immune cells,
may affect the angiogenic phenotype of the tumors [41]. Therefore, the
effects of rhLK8 on those factors cannot be ruled out. This possibility is
supported by the finding that plasminogen kringle 5, which has
significant sequence homology with rhLK8, can exert its antitumor
activity either by inhibiting the recruitment of tumor-associated
macrophages or by promoting the recruitment of neutrophils or
NKT lymphocytes [42,43].In conclusion, our results suggest that antiangiogenic therapy with
rhLK8 in combination with taxane-based conventional chemotherapy
could be a promising therapeutic approach to the treatment of patients
with ovarian cancer. Furthermore, the level of VEGF expressed or
produced by tumor cells may not be the absolute determinant as the
indication of antivascular therapy with rhLK8. Human apo(a) KV,
rhLK8, has recently entered phase I clinical trials in patients with cancer.
The safety and therapeutic outcomes of the combination of rhLK8 with
conventional chemotherapy should also be assessed.Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.04.005.
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